Nama Insights

Pacira BioSciences (PCRX)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Pacira BioSciences (PCRX) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.46B, a trailing price-to-earnings ratio of 14.0 and a free-cash-flow yield of 8.3%. Over the most recent reported fiscal year, revenue grew 3.6% and free cash flow per share fell 21.5%. Nama's AI scorecard rates it Buy, 7.2 out of 10.
AI scorecard
Buy · 7.2/10
Clearly positive, short of the top band. As of Nov 20, 2026.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-55.6%
How far the last close sits under the highest price of the past five years.
Market cap$1.46B
Trailing P/E14.0
Price / book2.0
Price / sales2.0
FCF yield8.3%
Dividend yield—
Gross margin78.7%
Operating margin3.0%
Net margin5.1%
Revenue growth (YoY)+3.6%
Revenue growth (3-yr annual)+2.9%
EPS growth (YoY)-18.1%
FCF/share growth (YoY)-21.5%
Beta0.2
ExchangeNASDAQ
SectorHealthcare
IndustryDrug Manufacturers Specialty Generic

PCRX earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.91). Beat the EPS estimate in 3 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 5, 2026 $0.70 $0.15 +366.7% $176.65M
Q2 2026 Aug 4, 2026 $0.73 $0.65 +12.3% $192.40M
Q1 2026 Apr 30, 2026 $0.60 $0.56 +7.1% $177.38M
Q4 2025 Feb 26, 2026 $0.57 $0.90 -36.7% $196.87M

PCRX analyst price target

Median target $36.50 from 6 analysts, ranging $28.00 – $36.50.

Drug Manufacturers Specialty Generic peers

TickerCompanyMarket capP/E
TAK Takeda Pharmaceutical $68.40B 43.7
TEVA Teva Pharmaceutical Industries $44.97B 16.3
HLN Haleon $39.67B 21.1
ZTS Zoetis $32.83B 12.2
UTHR United Therapeutics $23.81B 21.1
VTRS Viatris $22.79B 7.8
NBIX Neurocrine Biosciences $15.85B 15.7
ELAN Elanco Animal Health $13.14B 23.1
Explore live PCRX data on Nama Insights →

PCRX FAQ

Is PCRX a buy?
Nama's AI scorecard currently rates Pacira BioSciences Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PCRX's P/E ratio?
Pacira BioSciences trades at a trailing price-to-earnings ratio of 14.0.
When does PCRX report earnings?
Pacira BioSciences's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.91.
What is the PCRX price target?
The median analyst price target from 6 analysts is $36.50, with a range of $28.00 – $36.50.
Is PCRX Shariah compliant?
Nama's AAOIFI-style screen reads Pacira BioSciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.